Sanofi Buys TargeGen And Its Lead Myelofibrosis Drug For $75 Million Upfront
It's another earn-out based exit for venture capital, but TargeGen's backers could realize more than five times their initial investment if all milestones are achieved.
It's another earn-out based exit for venture capital, but TargeGen's backers could realize more than five times their initial investment if all milestones are achieved.